Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of which have attractive conditions for th...
Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Dengue fever and new patents.
Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever and provides an updated base case.
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and directed share issue in December-January.
Redeye comments on SynAct’s successful rights issue.
Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controlling inflammation through resolution rath...
